• 1
    Jonuleit H,Schmitt E,Stassen M,Tuettenberg A,Knop J,Enk AH. Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 128594.
  • 2
    Ng WF,Duggan PJ,Ponchel F,Matarese G,Lombardi G,Edwards AD,Issacs JD,Lechler RI. Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells. Blood 2001; 98: 273644.
  • 3
    Sakaguchi S,Sakaguchi N,Asano M,Itoh M,Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 115164.
  • 4
    Beyer M,Schultze JL. Regulatory T cells in cancer. Blood 2006; 108: 80411.
  • 5
    Dieckmann D,Plottner H,Berchtold S,Berger T,Schuler G. Ex vivo isolation and characterization of CD4+CD25+ T cells with regulatory properties from human blood. J Exp Med 2001; 193: 130310.
  • 6
    Hori S,Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 2004; 6: 74551.
  • 7
    Yagi H,Nomura T,Nakamura K,Yamazaki S,Kitawaki T,Hori S,Maeda M,Onodera M,Uchiyama T,Fujii S,Sakaguchi S. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004; 16: 164356.
  • 8
    Sakaguchi S,Ono M,Setoguchi R,Yagi H,Hori S,Fehervari Z,Shimizu J,Takahashi T,Nomura T. Foxp3+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 827.
  • 9
    Takahashi M,Nakamura K,Honda K,Kitamura Y,Mizutani T,Araki Y,Kabemura T,Chijiiwa Y,Harada N,Nawata H. An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis. Dig Dis Sci 2006; 51: 67786.
  • 10
    Dejaco C,Duftner C,Grubeck-Loebenstein B,Schirmer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology 2006; 117: 289300.
  • 11
    Kelsen J,Agnholt J,Hoffmann HJ,Romer JL,Hvas CL,Dahlerup JF. Foxp3+CD4+CD25+ T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease. Clin Exp Immunol 2005; 141: 54957.
  • 12
    Earle KE,Tang Q,Zhou X,Liu W,Zhu S,Bonyhadi ML,Bluestone JA. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin Immunol 2005; 115: 39.
  • 13
    Dieckmann D,Bruett CH,Ploettner H,Lutz MB,Schuler G. Human CD4+CD25+ regulatory, contact-dependent T cells, induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J Exp Med 2002; 196: 24753.
  • 14
    Longhi MS,Hussain MJ,Mitry RR,Arora SK,Mieli-Vergani G,Vergani D,Ma Y. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006; 176: 448491.
  • 15
    Viehl CT,Moore TT,Liyanage UK,Frey DM,Ehlers JP,Eberlein TJ,Goedegebuure PS,Linehan DC. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol 2006; 13: 12528.
  • 16
    Rudge G,Barrett SP,Scott B,van Driel IR. Infiltration of a mesothelioma by IFN-γ-producing cells and tumor rejection after depletion of regulatory T cells. J Immunol 2007; 178: 408996.
  • 17
    Badoual C,Hans S,Rodriguez J,Peyrard S,Klein C,Agueznay Nel H,Mosseri V,Laccourreye O,Bruneval P,Fridman WH,Brasnu DF,Tartour E. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006; 12: 46572.
  • 18
    Woo EY,Chu CS,Goletz TJ,Schlienger K,Yeh H,Coukos G,Rubin SC,Kaiser LR,June CH. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 476672.
  • 19
    Liyanage UK,Moore TT,Joo HG,Tanaka Y,Herrmann V,Doherty G,Drebin JA,Strasberg SM,Eberlein TJ,Goedegebuure PS,Linehan DC. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 275661.
  • 20
    Ormandy LA,Hillemann T,Wedemeyer H,Manns MP,Greten TF,Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65: 245764.
  • 21
    Petersen RP,Campa MJ,Sperlazza J,Conlon D,Joshi MB,Harpole DH,Jr,Patz EF,Jr. Tumor infiltrating FOXP3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006; 107: 286672.
  • 22
    Ichihara F,Kono K,Takahashi A,Kawaida H,Sugai H,Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patient with gastric and esophageal cancers. Clin Cancer Res 2003; 9: 44048.
  • 23
    Wolf D,Wolf AM,Rumpold H,Fiegl H,Zeimet AG,Muller-Holzner E,Deibl M,Gastl G,Gunsilius E,Marth C. The expression of the regulatory T cells-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005; 11: 832631.
  • 24
    Kono K,Kawaida H,Takahashi A,Sugai H,Mimura K,Miyagawa N,Omata H,Fujii H. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006; 55: 106471.
  • 25
    Curiel TJ,Coukos G,Zou L,Alvarez X,Cheng P,Mottram P,Evdemon-Hogan M,Conejo-Garcia JR,Zhang L,Burow M,Zhu Y,Wei S, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 9429.
  • 26
    Ishida T,Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 2006; 97: 113946.
  • 27
    Japanese Gastric Cancer Associations. Japanese classification of gastric carcinoma, 2nd (English Edition). Gatric Cancer 1998; 1: 1024.
  • 28
    Fontenot JD,Rasmussen JP,Williams LM,Dooley JL,Farr AG,Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor Foxp3. Immunity 2005; 22: 32941.
  • 29
    Pillai V,Ortega SB,Wang CK,Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 2007; 123: 1829.
  • 30
    Allan SE,Crome SQ,Crellin NK,Passerini L,Steiner TS,Bacchetta R,Roncarolo MG,Levings MK. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007; 19: 34554.
  • 31
    Zheng SG,Wang JH,Gray JD,Soucier H,Horwitz DA. Natural and induced CD4+CD25+ cells educate CD4+CD25 cells to develop suppressive activity: the role of IL-2. TGF-β, and IL-10. J Immunol 2004; 172: 521321.
  • 32
    Bates GJ,Fox SB,Han C,Leek RD,Garcia JF,Harris AL,Banham AH. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24: 537380.
  • 33
    Hiraoka N,Onozato K,Kosuge T,Hirohashi S. Prevalence of FOXP3+ regulatory T cells increased during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006; 12: 542334.
  • 34
    Hirahara K,Liu L,Clark RA,Yamanaka K,Fuhlbrigge C,Kupper TS. The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. J Immunol 2006; 177: 448894.
  • 35
    Miller AM,Lundberg K,Özenci V,Banham AH,Hellström M,Egevad L,Pisa P. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006; 177: 7398405.
  • 36
    Imai T,Nagira M,Takagi S,Kakizaki M,Nishimura M,Wang J,Gray PW,Matsushima K,Yoshie O. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol 1999; 11: 818.
  • 37
    Vulcano M,Albanesi C,Stoppacciaro A,Bagnati R,D'Amico G,Struyf S,Transidico P,Bonecchi R,Del Prete A,Allavena P,Ruco LP,Chiabrando C, et al. Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur J Immunol 2001; 31: 81222.